LYNK Pharmaceuticals Valuation, Funding & Investors

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.

Onconic Therapeutics Inc is a company that researches and develops new drugs for gastrointestinal diseases and anticancers, which have large unmet medical needs. Its pipeline products are Zataprazan(OCN-101) and OCN-201.

Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company’s products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.

Juvenescence is a British Virgin Islands-registered investment firm targeting therapies for human longevity and age-related diseases. The company has launched subsidiaries like Juvenescence Therapeutics and supports pipeline assets in metabolic health, neurodegeneration, and regeneration. Backed by partnerships with institutions such as the Buck Institute for Research on Aging, Juvenescence in-licenses compounds from academia to develop drugs extending healthspan.

Ollin Biosciences is an Austin, Texas-based clinical-stage biopharmaceutical company that acquires and develops bispecific antibody therapies for vision-threatening eye diseases rather than pursuing in-house drug discovery. Its lead candidate, OLN324, is a VEGF/Ang2 bispecific antibody licensed from China's Innovent Biologics that is advancing toward Phase 3 trials for diabetic macular edema and wet age-related macular degeneration. A second program, OLN102, licensed from VelaVigo, is a TSHR/IGF-1R bispecific antibody in development for thyroid eye disease and Graves' disease.

TORL BioTherapeutics is a UK-headquartered clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibodies for oncology indications with high unmet needs. Its pipeline includes TORL-1-23, a next-generation ADC targeting solid tumors, advancing through Phase 1 trials. TORL employs proprietary payload-linker technologies to enhance efficacy and safety profiles. With facilities in London and partnerships in drug discovery, the firm addresses breast, lung, and other cancers through differentiated therapeutic candidates.

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the cell preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.

Rivus Pharmaceuticals is a San Diego-based biopharma company developing controlled metabolic accelerators for cardio-metabolic diseases. Its lead candidate targets obesity and heart failure by modulating fat metabolism. Clinical trials in phase 2 enroll patients across the US and Europe.

Dewpoint Therapeutics is a Boston, Massachusetts-headquartered biotechnology company founded in 2018 modulating biomolecular condensates for diseases like ALS and cancer. The Condensate Dialysis platform screens compounds disrupting pathological condensates using AI-driven imaging, with lead candidates targeting FUS protein aggregates entering Phase 1 trials in 2023.

TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.